Cure My Disease

Don't miss your cure!

 Log in / Sign up

New diabetes drug tirzepatide tested in chinese patients

NCT ID NCT05963022

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tested the drug tirzepatide (a once-weekly injection) against a placebo in 206 Chinese adults with type 2 diabetes. The goal was to see if tirzepatide could safely lower blood sugar levels. Participants had to have stable weight and a BMI of 23 or higher. The study is now complete, and results will show how well tirzepatide works for this population.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tirzepatide (a once-weekly injection)
What this could lead to
If successful, tirzepatide could offer a new, effective option for managing blood sugar in Chinese patients with type 2 diabetes.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. Tirzepatide may cause side effects like nausea or diarrhea, and it is not a cure—patients will need ongoing treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

206 people

The number who actually took part.

Started

Aug 2023

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have Type 2 Diabetes * Have HbA1c ≥7.0% (≥53 mmol/mol) to ≤9.5% (≤80 mmol/mol) despite diet and exercise treatment * Are of stable weight 5%) during the 90 days preceding screening and agree not to initiate a diet and/or exercise program during the study with the intent of reducing body weight other than the lifestyle and dietary measures for diabetes treatment * Have Body Mass Index (BMI) ≥23.0 kilogram per square meter (kg/m²) Exclusion Criteria: * Have Type 1 Diabetes * Have a history of chronic or acute pancreatitis any time prior to study entry * Are currently receiving treatment for diabetic retinopathy and/or macular edema * Have a history of ketoacidosis or hyperosmolar state/coma * Have a history of New York Heart Association Functional Classification IV congestive heart failure (CHF) * Have acute or chronic hepatitis including a history of autoimmune hepatitis * Use of insulin 1-year preceding screening and between screening and baseline; use of any antihyperglycemic medication 90 days preceding screening and between screening and baseline.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

Contacts and locations

Locations

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu, 212000, China

  • Chengdu Fifth People's Hospital

    Chengdu, Sichuan, 611130, China

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, 100853, China

  • Dalian Municipal Central Hospital Affiliated of Dalian Medical University

    Dalian, Liaoning, 116033, China

  • Dalian University - The Affiliated Zhongshan Hospital

    Dalian, Liaoning, 116001, China

  • Hainan General Hospital

    Haikou, Hainan, 570311, China

  • Huizhou Municipal Central Hospital

    Huizhou, Guangdong, 516001, China

  • Huzhou Central Hospital

    Huzhou, Zhejiang, 313000, China

  • Jiading District Central Hospital

    Shanghai, Shanghai Municipality, 201800, China

  • Jiangxi Pingxiang People's Hospital

    Pingxiang, Jiangxi, 337055, China

  • Jinan Central Hospital

    Jinan, Shandong, 250013, China

  • Nanjing First Hospital

    Nanjing, Jiangsu, 210012, China

  • Nanjing Medical University - Nanjing Jiangning Hospital

    Nanjing, Jiangsu, 211100, China

  • Panjin Liaoyou Baoshihua Hospital

    Liaoyou, Liaoning, 124009, China

  • Pudong New Area People's Hospital Shanghai

    Shanghai, Shanghai Municipality, 201200, China

  • Shunde Hospital of Southern Medical Univesity

    Foshan, Guangdong, 528399, China

  • The First Affiliated Hospital of Henan University of Science &Technology

    Luoyang Shi, Henan, 471003, China

  • The First Affiliated Hospital of Nanyang Medical College

    Nanyang, Henan, 473007, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, 215006, China

  • The First Affiliated Hospital of Xi'an Medical University

    Xi'an, Shaanxi, 710077, China

  • The First People's Hospital of Changde City

    Changde, Hunan, 415003, China

  • The Fourth Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, 150001, China

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, 210011, China

  • The Second Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, 450014, China

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, 300052, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, 610041, China

  • Yichang Central People's Hospital

    Yichang, Hubei, 443003, China

  • Zunyi First People's Hospital

    Zunyi, Guizhou, 563002, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.